PharmaEssentia Corporation
6446
Classificação em ações
#1436
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Preço da ação
$37.20
Valor de mercado
$15.39B
Variação (1 dia)
1.30%
Variação (1 ano)
144.58%
País
TW
Negociar PharmaEssentia Corporation (6446)
Categoria
Healthcare
Receita da PharmaEssentia Corporation (6446)
Receita em Jun 2026 TTM: $659.89M
De acordo com os últimos relatórios financeiros da PharmaEssentia Corporation, a receita atual da empresa (TTM) é $659.89M. Em 2023, a empresa obteve uma receita de $166.40M um aumento em relação a a receita do ano 2022, que foi de $93.99M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da PharmaEssentia Corporation de 2010 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $659.89M | 122.49% |
| 2024 | $296.59M | 78.25% |
| 2023 | $166.40M | 77.03% |
| 2022 | $93.99M | 296.82% |
| 2021 | $23.69M | 19.41% |
| 2020 | $19.84M | 94.10% |
| 2019 | $10.22M | 1,091.15% |
| 2018 | $857.94K | 530.65% |
| 2017 | $136.04K | -19.37% |
| 2016 | $168.73K | -52.08% |
| 2015 | $352.09K | -16.40% |
| 2014 | $421.16K | -82.61% |
| 2013 | $2.42M | 147.06% |
| 2012 | $980.24K | 88.40% |
| 2011 | $520.29K | -71.45% |
| 2010 | $1.82M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 901.94% |
IN
|
